US 10,588,951 B2 · Compound comprising an autoantigenic peptide and a carrier with a MHC binding motif

Abstract

The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif X-X-X-X-X-X-X, wherein at least one amino acid residue X is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a MHC binding motif being linked to said peptide as well as pharmaceutical compositions comprising said compound and the use of said compound or pharmaceutical composition for the treatment of a disease, such as an inflammatory joint disease. The subject matter of the application is exemplified with peptides derived from type II collagen such as peptides having at least the sequence AGFKGEA, or IAGFKGEQPKG, or the peptide AAAKAAA. Preferably a hydroxylysine in the peptides are glycosylated.

Claims10

Dependent claims

A compound comprising (a) a peptide and (b) a carrier, wherein said peptide is bound within the peptide-binding site of said carrier, and

a. said peptide consists of IAGFKGEQGPKG (SEQ. ID. NO.:
7), wherein at least the lysine at position 5 of said peptide is a glycosylated hydroxylysine, and
b. said carrier comprises at least the variable region of a naturally occurring MHC class II molecule wherein said carrier does not comprise the transmembrane domain and cytoplasmic domain of the alpha and beta chains of said naturally occurring MHC class II molecule and said alpha and beta chains are linked to each other by a leucine zipper or an immunoglobulin, and
wherein said carrier comprises the variable region of an MHC class II molecule selected from the group consisting of DRB1*0401/DRA, DRB1*0101/DRA, and DRB1*1001/DRA.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

14/658,962Filed 16 Mar 2015 · continuation

Priority

SE 050253017 Nov 2005

Published

US 2015/0231216 A120 Aug 2015

Granted

17 Mar 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 39/0008
Vertebrate antigens: antigens related to auto-immune diseases; Preparations to induce self-tolerance
A61K 47/6425
Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is…: the…
A61K 47/6811
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a protein or peptide, e.g. transferrin or…
A61K 47/6843
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a material from…

Family

Application60/758,481Us provisional application · filed 12 Jan 2006

PCT/SE2006/001290Parent of this continuation · filed 15 Nov 2006

US 2015/0231216 A1Pre-grant publication · published 20 Aug 2015

Application12/092,724Parent of this continuation

US 2009/0227516 A1Published application

US 10,588,951 B2This patent

From the US filing history. Foreign family members aren’t listed.

Compound comprising an autoantigenic peptide and a carrier with a MHC binding motif

Life of this patent

Compound comprising an autoantigenic peptide and a carrier with a MHC binding motif

Life of this patent

Abstract

Claims10